Phase 2 Trial of Rexahn’s Supinoxin for Metastatic TNBC Doses First Patient

Phase 2 Trial of Rexahn’s Supinoxin for Metastatic TNBC Doses First Patient
The Phase 2a trial assessing the safety and efficacy of Rexahn Pharmaceuticals' Supinoxin — an oral inhibitor of the β-catenin pathway in metastatic triple negative breast cancer (TNBC) patients who failed prior treatments — has dosed its first patient. Rexahn CEO Peter D. Suzdak, PhD, called the event "a major milestone" for Supinoxin. “Our decision to focus initially on triple negative breast cancer underscores our commitment to developing our targeted treatments for cancers that are difficult to treat and for which there are limited treatment options," Suzdak said in a news release  "There is currently no approved drug treatment for TNBC and no established standard of care, so there is a tremendous unmet medical need.” Supinoxin is an orally administered, small molecule that inhibits the β-catenin pathway by preventing its interaction with the protein p68. The β-catenin pathway is often activated in cancer cells, leading to the production of various tumor-promoting genes and inducing tumor proliferation and metastasis. Rexahn's therapy has shown promising anti-tumor activity, inhibiting tumor growth in preclinical models of TNBC. In addition, experiments in lab-cultured cells revealed that it works in synergy against the disease with commonly used drugs like Taxol (paclitaxel), Platinol (cisplatin) and Adriamycin (doxorubicin). “Supinoxin has a unique mechanism of action,” said Ely Benaim, MD, the company's chief medical officer. “It targets a key biological
Subscribe or to access all post and page content.